May - 2021
| Previous Next | Showing Journal 8 of 10 |
Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal SyndromeF Wong, C Pappas, M Curry, et al for the CONFIRM Study Investigators New Eng J Med, 2021, 384:818-828 This page is only available to Crit-IQ subscribers. To view the rest of this review and gain access to our vast array of critical care teaching tools including podcasts, vodcasts, modules, exam preparation tools, teaching aids and much more, login here, or Become a Member to register |
May |
Previous Comments
No Comments yet.
Comment
Terlipressin is a synthetic vasopressin analogue with vasoconstrictor activity in the splanchnic and systemic vasculature, resulting in decreased portal blood inflow and reduced portal hypertension, the main cause of the hemodynamic abnormalities associated with advanced cirrhosis....